FDA Greenlights IND for Chinese Biotech Targeting Thymic Carcinoma

FDA Greenlights IND for Chinese Biotech Targeting Thymic Carcinoma

A Chinese-based biotech company’s investigational new drug application (IND) was given the nod by the U.S. Food and Drug Administration (FDA), meaning that Alphamab Oncology (traded on the Hong Kong exchange as 9966) can commence its open label, multi-center Phase 2 pivotal clinical trial in the United States. The goal: investigate and evaluate the efficacy, safety and tolerability of their investigational cancer therapy known as KN046 for the treatment of thymic carcinoma.

What is thymic carcinoma?

Thymic carcinoma is a rare but highly aggressive thymic tumor, and the most aggressive subtype of thymic epithelial tumors, accounting for about 20%. The number of patients with thymic carcinoma is about 4,200 to 6,000 in China per year, and 1,400 to 2,000 in the United States per year. Inoperable or metastatic thymic carcinoma has a very poor prognosis, and there is currently no approved standard treatment for patients who have failed platinum-based chemotherapy. The median overall survival after late-line chemotherapy or targeted therapy is less than 12 months, and there is an urgent need for better options to improve the efficacy.

What is KN046?

KN046 is a bispecific antibody targeting PD-L1 and CTLA-4 immune checkpoints. It can more effectively activate T-cells and enhance the T-cells cancer killing ability. In a phase I clinical study conducted in Australia, KN046 showed a 75% disease response rate and 100% disease control rate in patients with thymic epithelial tumors. The research data was presented at the 21st World Conference on Lung Cancer (WCLC 2020). In September 2020, KN046 was granted the orphan drug designation by the FDA for the treatment of thymic epithelial tumors. In January 2021, the Phase II pivotal clinical trial of KN046 for the treatment of thymic carcinoma (clinical trial No.: ENREACH-Thymic) completed enrollment of the first patient in China.

What is the status of various clinical trials?

There are about 20 clinical trials of KN046 in different stages covering more than 10 types of tumors, including NSCLC, TNBC, ESCC, HCC and pancreatic cancer in Australia and China. The results of these clinical trials have shown an advantage in survival for patients. Alphamab has received FDA clearance to enter phase Ⅱ trial of KN046 based on the clinical results in China and Australia. Moreover, KN046 has obtained the U.S. FDA’s orphan drug designation for thymic epithelial tumor in September 2020. Two pivotal clinical trials are currently being conducted.

Alphamab Oncology background

Alphamab Oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. On December 12, 2019, the Company was listed in the mainboard of Hong Kong Stock Exchange with the code 9966.

Alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. Its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a Covid-19 multifunctional antibody. Four products have advanced into phase I-III clinical trials or pre-marketing stages in China, the United States, Japan and Australia. The BLA for Envafolimab (KN035) has been accepted and granted Priority Review by the National Medical Products Administration (NMPA).

The Company also has state-of-the-art manufacturing capabilities designed and built to meet NMPA and EU/FDA’s cGMP standards and a complete quality system which has passed the on-site inspection of an European Union qualified person. Alphamab Oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in China as well as around the world.

Call to ActionTrialSite will monitor the study involving thymic carcinoma and communicate any updates.

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.